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Summary
Blood transfusions are a relatively common occur-
rence after performing any percutaneous coronary inter-
vention (PCI). Although guidelines for blood transfusion
have been previously specified, retrospective analysis of
transfusion practices have suggested that these guide-
lines are rarely applied. We describe a model for the
application of a continuous quality improvement pro-
gram including benchmarking and available guidelines
for blood transfusion, aimed toward reducing transfusion
rates among patients undergoing PCI.
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Introduction
Advancements in pharmacotherapy and in catheter
technology have resulted in improved outcomes from
acute coronary syndromes (ACS) and in increased safety
and success rates of percutaneous coronary intervention
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(PCI). Unfortunately, development of major bleeding
continues to be the most frequent noncardiac compli-
cation of ACS1–3 (Fig. 1) and of PCI.4 Importantly,
although it is unquestionable that the safety of blood sup-
ply has improved significantly, blood transfusion is still
associated with a small risk of blood-borne infections.5,6
In addition, recent studies have suggested a relationship
between major bleeding and an increased risk of in-
hospital death among patients with ACS (Fig. 2),7 and a
relationship between blood transfusion and an increased
risk of adverse outcomes and in-hospital mortality among
critically ill patients,8 patients with ACS,7,9 and patients
undergoing PCI.10
The pathophysiology surrounding the relationship bet-
ween blood transfusion and an increased risk of death
remains unclear. In general, blood transfusions are asso-
ciated with a small, though not insignificant, risk of viral
transmission,5 bacterial contamination, and hemolytic
reactions.11 In addition, some studies have shown a
relationship between blood transfusion and an increased
risk of acute respiratory distress syndrome in critically
ill patients.12 Other studies have shown a significantly
higher rate of nosocomial infections among critical care
patients transfused with red blood cells when compared
with patients who did not received a blood transfusion.13
Postulated mechanisms surrounding these increased risks
include a systemic inflammatory response triggered by
blood transfusion, nonspecific immunosuppression medi-
ated by a graft-versus-host reaction, by an increase in
T-lymphocyte suppressor and natural killer cell func-
tion, and by a decrease in activity of monocytes and
macrophages.11 In addition, it has been suggested that
tissue hypoxemia mediated by occlusion of the microvas-
culature might play an important role in the adverse
effects of blood transfusion in critically ill patients.
Risk Factors for Major Bleeding
Several studies have evaluated risk factors associated
with an increased risk of major bleeding in patients




















FIG. 1 Frequency of major bleeding in the Global Reg-
istry of Acute Coronary Events (GRACE). STEMI =
ST-elevation myocardial infarction. Reproduced from Ref.























FIG. 2 In-hospital mortality according to development of
major bleeding in patients with acute coronary syndromes.
STEMI = ST-elevation myocardial infarction. Data from
the Global Registry of Acute Coronary Events (GRACE).
with ACS, and in patients undergoing PCI. Female sex,
advanced age, renal insufficiency, and history of bleed-
ing have been consistently associated with an increased
risk of bleeding,7 and with an increased risk of vas-
cular complications after PCI.14,15 In addition, renal
dysfunction has been identified as an important corre-
late of adverse outcomes after percutaneous and surgical
cardiac procedures. The postulated mechanisms of the
association between renal insufficiency and an increased
risk of bleeding include platelet dysfunction,16 impaired
clearance of unfractionated heparin and of low molecu-
lar weight heparin,17,18 and additional abnormalities in
the coagulation cascade. In addition to these baseline
comorbidities, pharmacological and mechanical thera-
peutic interventions, in particular, the use of thrombolytic
agents GP IIb/IIIa receptor blockers, and of invasive pro-
cedures, have been previously identified as independent
factors associated with major bleeding.7 Human error
and equipment limitations might play a further role in
the development of major bleeding in patients under-
going PCI.19 Finally, the recent introduction of newer
antithrombotic agents in the management of patients with
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FIG. 3 Venn diagram illustrating the number of appro-
priate and inappropriate blood transfusions according to
the criteria used in a retrospective analysis of transfusion
practice after percutaneous coronary intervention in a sin-
gle institution.23 In that analysis, a hematocrit <24% was
included as an additional appropriate trigger for blood trans-
fusion in asymptomatic patients at risk of ischemia. Trans-
fusions that fulfill only one criterion are enclosed by one
circle. Transfusions that fulfill two criteria are enclosed by
three circles, whereas transfusions that fulfill three criteria
are enclosed in all circles. Transfusions that do not meet
any criteria are outside the circles, while appropriate trans-
fusions are enclosed in the shaded area.23
promising role in reducing the risk of major bleeding
among these patient groups.20,21
The identification of risk factors for major bleed-
ing and for blood transfusion allows the development
of risk-adjustment models that can be used to identify
patients at higher risk of bleeding, and for the assess-
ment of the effectiveness of quality improvement efforts
aimed toward reducing bleeding complications and trans-
fusions.
Guidelines for Blood Transfusion
In 1992, the American College of Physicians proposed
guidelines for blood transfusion.22 According to those
guidelines, the decision to administer a blood transfusion
to a patient should not be based on a hemoglobin trig-
ger, but rather on a patient’s symptoms and on the risk
of ischemic complications from acute anemia. In the set-
ting of acute anemia secondary to blood loss, crystalloid
infusions should be tried first, and single units should
be transfused rather than what has been anecdotally the
standard of 2 units of packed red blood cells. In addition,
the decision to proceed with blood transfusion should be
based on the presence of symptoms defined as transient
ischemic attack, syncope, chest pain, and sinus tachy-
cardia, and on the basis of a patient’s risk of ischemic
complications from the acute blood loss. A patient’s risk
is defined as the presence of unrevascularized coronary
artery territory, valvular heart disease, and congestive
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BMC2 pocket guide
Blood transfusion for adult cardiology patients
BMC2
Considering red blood cell transfusion
Is the patient having symptoms or
signs of acute anemia? i.e. do they
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Is patient at risk for ischemic complications?
i.e. do they have any of the following?
History of CHF
History of stroke or TIA




FIG. 4 Clinical algorithm with guidelines for blood transfusion developed to aid the decision-making process for adminis-
tering blood transfusion. The other side of the index card includes references and a brief explanation with the rationale for
using guidelines for blood transfusion. The algorithm is printed on a laminated index card that is distributed to each physician
rotating on the cardiology service.∗Greater than 50% stenosis in any major epicardial artery or branch. †Consider use of one
unit red blood cells, which should raise the hematocrit by 3%. Abbreriations: BMC2 = Blue Cross Blue Shield of Michigan
Cardiovascular Consortium; CHF = congestive heart failure; HCT = hematocrit; TIA = transient ischemic attack. Source:
University of Michigan Interventional Cardiology Service.
heart failure. According to the guidelines, in the absence
of risk factors and of symptoms, patients should not be
given a blood transfusion regardless of their hemoglobin
level.
Few studies have attempted to assess appropriateness
of blood transfusion according to these criteria.23,24 In
one such study,23 transfusion events in 628 patients
undergoing PCI were evaluated retrospectively. Blood
transfusions were administered after 8.9% of interven-
tions (56 of 628) and were more frequent in patients
undergoing coronary stenting, in women, elderly patients,
patients undergoing PCI for acute myocardial infarc-
tions, and in patients undergoing procedures that required
placement of an intra-aortic balloon pump. After appli-
cation of the guidelines for blood transfusion, 64% of
transfusion events could be classified as inappropriate
(Fig. 3). Although the retrospective study design can be
viewed as an important limitation, the results suggested
that application of the American College of Physician
Guidelines for blood transfusion might have the potential
to reduce the frequency of blood transfusion.
Reduction of Blood Transfusion Rates as a Model
for Quality Improvement
In light of the factors described above, and the fact
that in analyzing blood transfusion practices in a regional
PCI consortium including five hospitals, a relatively
high transfusion rate was observed at the University of
Michigan when compared with the consortium. In 1998,
the University of Michigan Interventional Cardiology
Service decided to set blood transfusion as a target for
quality improvement.
An algorithm with guidelines for blood transfusion
was, therefore, developed and included in a single index
card (Fig. 4). The index card included on one side the
algorithm to aid the decision-making process for admin-
istering blood transfusion, and on the other side, the
rationale and supporting data for the guidelines. The card
was circulated among the interventional cardiology staff,
the general cardiology staff and trainees, and additional
reminders were provided on a monthly basis. In addition,
detailed quarterly reports were provided to each indi-
vidual interventional cardiologist. The reports included
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three columns with aggregate consortium data, aggre-
gate hospital data, and individual operator data. Each
column included comorbidities, demographic data, pro-
cedural data, and outcome data of all patients undergoing
PCI. The purpose of the report was to provide feedback
to individual operators, and to allow operators to com-
pare their practices with the hospital practice and the
consortium practice.
As shown in Figure 5, in 1998, the transfusion rate
was significantly higher in the index hospital when
compared with the consortium. Over the following 3
years, the frequency of blood transfusions in our hospital
decreased progressively and, in 2001, the transfusion rate
was the lowest within the consortium (Fig. 5).
Conclusion
The past decade has been characterized by an empha-
sis on improving quality of care of patients with ACS,
and of patients undergoing cardiovascular procedures. In
addition, several studies have brought attention to the
importance of avoiding bleeding, and to the controversy
surrounding the relationship between blood transfusion
and an increased risk of short- and long-term mortal-
ity. Application of a continuous quality improvement
approach such as the one used in our evaluation, with the
inclusion of benchmarking and of available guidelines,
appears a promising approach to reducing the frequency
of blood transfusion in patients with ACS, and in patients
undergoing PCI. Further studies are needed to assess the
effectiveness of this approach on a larger scale.
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FIG. 5 Standardized transfusion ratios for the index hospi-
tal versus all other hospitals during the 4 years of follow-up.
The data represent the ratio of observed over predicted
transfusion rates. Predicted transfusion rates were estimated
using multivariate logistic regression modeling. A ratio
above 1 indicates that the observed rate is higher than pre-
dicted. Tx = transfusion.
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